Hanmi to distribute Wakamoto’s MaQuid to treat diabetic macular edema
Published: 2013-07-25 06:57:00
Updated: 2013-07-25 06:57:00
Hanmi Pharmaceutical said Tuesday that it has signed a distribution agreement with a Japanese company Wakamoto for the exclusive sale of Wakamoto’ MaQaid for the treatment of diabetic macular edema (DME), a sight-threatening eye disease that occurs in people with diabetes.
An injection designe...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
